Market Place
Sourcing Support
NanoViricides Advances NV-387 to Ph 2 for MPOX, RSV, Influenza
15 Nov 2024 //
ACCESSWIRE
NanoViricides President Dr. Diwan to Present at the PODD Conference
22 Oct 2024 //
ACCESSWIRE
NanoViricides President Dr. Diwan Interviwed in PODD Podcast
15 Oct 2024 //
ACCESSWIRE
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
08 Oct 2024 //
ACCESSWIRE
NanoViricides Files Annual Report: NV-387 Progressing To Ph 2
30 Sep 2024 //
ACCESSWIRE
NanoViricides Investigates MEURI Protocol For NV-387 To Treat MPOX
26 Aug 2024 //
ACCESSWIRE
NanoViricides Progresses Towards Phase II Trial Of NV-387 Antiviral
19 Aug 2024 //
ACCESSWIRE
NanoViricides Updates On NV-387 Clinical Program And Strategy
08 Aug 2024 //
ACCESSWIRE
Two Reports Highlight NanoViricides` Potential In Viral Therapy
01 Aug 2024 //
ACCESSWIRE
NanoViricides Plans Next Phase For Multi-Respiratory Virus Drug Trials
11 Jul 2024 //
ACCESSWIRE
NanoViricides Positioned With Clinical, Pre-Clinical Pipeline, Virus-Kill Tech
01 Jul 2024 //
ACCESSWIRE
NV-387 Broad-Spectrum Antiviral Could Combat Bird Flu H5N1, Says NanoViricides
24 Jun 2024 //
ACCESSWIRE
NV-387 Antiviral Protects Lungs In Lethal Influenza A Animal Model
20 Jun 2024 //
ACCESSWIRE
NV-387 Shows Ideal Blood Profile For Sustained Antiviral Effect
12 Jun 2024 //
ACCESSWIRE
NV-387: Sustained Release Enables Infrequent Dosing For Antivirals
04 Jun 2024 //
ACCESSWIRE
Broad Antiviral For RSV COVID Flu Other Viruses In Development
29 May 2024 //
ACCESSWIRE
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
23 May 2024 //
ACCESSWIRE
Oral NV-387 Shows Normal Lung Histology In Lethal RSV
20 May 2024 //
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
15 May 2024 //
ACCESSWIRE
NanoViricides At EF Hutton Conference In NYC On May 15
10 May 2024 //
ACCESSWIRE
Novel Broad-Spectrum Antiviral Active Against Smallpox/Mpox
08 May 2024 //
ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
06 May 2024 //
ACCESSWIRE
NanoViricides: Phase I NV-387 Trial Completed, Data Lock Soon
30 Apr 2024 //
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
15 Feb 2024 //
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
15 Nov 2023 //
ACCESSWIRE
NanoViricides Announces thatTrials of Its Broad-Spectrum Antiviral Drug NV-CoV-2
29 Jun 2023 //
ACCESSWIRE
NanoViricides, Inc. to Present at the BIO International Convention
31 May 2023 //
ACCESSWIRE
NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference
04 May 2023 //
GLOBENEWSWIRE
NanoViricides is Expanding its Broad-Spectrum Antiviral Program
25 Apr 2023 //
ACCESSWIRE
NanoViricides Signs Agreement for Evaluation of COVID-19 Drug Candidates
04 Apr 2023 //
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report
15 Feb 2023 //
ACCESSWIRE
NanoViricides Has Filed Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage
15 Nov 2022 //
ACCESSWIRE
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy
09 Aug 2022 //
ACCESSWIRE
NanoViricides Begins Drug Development to Combat Monkeypox Virus
04 Aug 2022 //
ACCESSWIRE
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
25 Apr 2022 //
ACCESSWIRE
NanoViricides Completes Oral Gummies and Lung Inhalation
15 Nov 2021 //
BIOSPACE
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program
13 Oct 2021 //
BLOOMBERG
NanoViricides Files its Annual Report
13 Oct 2021 //
BIOSPACE
NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development
05 Oct 2021 //
PRNEWSWIRE
Significantly Improved Safety Profile and Metabolism of Remdesivir
22 Sep 2021 //
PRNEWSWIRE
NanoViricides surges 60% on COVID remdesivir encapsulation data
21 Sep 2021 //
SEEKINGALPHA
NanoViricides, Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective
09 Mar 2021 //
NASDAQ
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment
02 Mar 2021 //
PRESS RELEASE
Clinical Study Begins for the First Oral Systemic Nitric Oxide Based Therapeutic
26 Oct 2020 //
PRNEWSWIRE
Coronavirus Drug Development Update from NanoViricides, Inc
02 Sep 2020 //
WORLDPHARMA
Safety & Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal
08 Jul 2020 //
BIOSPACE
NanoViricides Announces Addition to Russell Microcap(R) Index
30 Jun 2020 //
BIOSPACE
NanoViricides Announces Completion of $10.2 Million Registered Direct Offering
26 May 2020 //
MARKETWATCH
Growing Number of Collaborations in U.S. Sectors Fueling Positive Coronavirus
04 May 2020 //
PRNEWSWIRE
NanoViricides Announces Completion of Production of its Lead Candidate
13 May 2019 //
PR NEWSWIRE
NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering
27 Feb 2019 //
PR NEWSWIRE
